Elicio Grants 21,210 Stock Options to New Employee
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 16 2026
0mins
Should l Buy ELTX?
Source: Yahoo Finance
- Stock Option Grant: On April 15, 2026, Elicio Therapeutics granted 21,210 inducement stock options to a new employee at an exercise price of $11.78 per share, in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent and enhancing the company's competitive edge.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, ensuring employee retention and loyalty during the vesting period, which is crucial for maintaining organizational stability.
- Clinical Development Progress: Elicio's ELI-002 7P program targets mKRAS-positive pancreatic and colorectal cancers, aiming to improve patient survival rates through low-cost, rapidly manufactured immunotherapies, with recent data showing a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months, indicating promising clinical outcomes.
- Technological Innovation Advantage: Elicio's Amphiphile technology enhances the education and activation of cancer-specific T cells, offering faster drug availability and lower costs compared to traditional immunotherapy, aligning with market demands for effective and economical treatment options.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELTX
Wall Street analysts forecast ELTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.850
Low
13.00
Averages
15.50
High
18.00
Current: 11.850
Low
13.00
Averages
15.50
High
18.00
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elicio Grants 21,210 Stock Options to New Employee
- Stock Option Grant: On April 15, 2026, Elicio Therapeutics granted 21,210 inducement stock options to a new employee at an exercise price of $11.78 per share, in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent and enhancing the company's competitive edge.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, ensuring employee retention and loyalty during the vesting period, which is crucial for maintaining organizational stability.
- Clinical Development Progress: Elicio's ELI-002 7P program targets mKRAS-positive pancreatic and colorectal cancers, aiming to improve patient survival rates through low-cost, rapidly manufactured immunotherapies, with recent data showing a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months, indicating promising clinical outcomes.
- Technological Innovation Advantage: Elicio's Amphiphile technology enhances the education and activation of cancer-specific T cells, offering faster drug availability and lower costs compared to traditional immunotherapy, aligning with market demands for effective and economical treatment options.
See More
Elicio Therapeutics Reports FY GAAP EPS and Cash Position
- Financial Performance: Elicio Therapeutics reported a FY GAAP EPS of -$2.58, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $18.6 million, an increase from $17.6 million in 2024, reflecting improved cash management practices.
- Operational Support Outlook: The company expects its current cash and projected at-the-market program proceeds to sustain operations into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 event-driven DFS analysis in 1H 2026, demonstrating confidence in future operations.
- Funding Situation: Elicio raised approximately $4.9 million in net proceeds in Q4 2025 and $6.3 million to date in Q1 2026 through its established at-the-market program, enhancing liquidity to support R&D and operations.
See More
Elicio Therapeutics Grants 22,400 Stock Options to Attract New Employees
- Stock Option Incentive: On January 15, 2026, Elicio Therapeutics granted 22,400 inducement stock options to two new employees to attract talent in compliance with Nasdaq Listing Rule 5635(c)(4), which is expected to enhance the company's talent acquisition and team strength.
- Option Pricing: Each stock option is priced at $7.81 per share based on the closing price on the grant date, which will allow employees to gradually acquire company shares over four years, thereby increasing employee loyalty in the long term.
- Clinical Research Progress: Elicio's ELI-002 immunotherapy demonstrated a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months in a randomized trial for mKRAS-positive pancreatic cancer, indicating its potential in cancer treatment and likely driving future market demand.
- Technological Innovation: Elicio's AMP technology aims to enhance the education and activation of cancer-specific T cells, which is expected to provide the company with a strategic advantage in the competitive biotechnology market, particularly in the field of immunotherapy for high-prevalence cancers.
See More
Elicio Grants 157,193 Stock Options to Attract New Employees
- Employee Incentive Program: On December 15, 2025, Elicio granted 157,193 inducement stock options to three new employees, aiming to attract talent while complying with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to talent acquisition.
- Stock Option Details: Each stock option has an exercise price of $8.52 per share, based on the closing price on the grant date, with vesting over four years, reflecting the company's recognition of long-term employee contributions.
- Clinical Development Outlook: Elicio focuses on developing immunotherapies for high-prevalence cancers, particularly ELI-002 for mKRAS-positive pancreatic and colorectal cancers, aiming to meet market demand through low-cost and rapid production, thereby enhancing competitive positioning.
- Future Expansion Plans: Elicio intends to expand ELI-002 to other mKRAS-positive cancers, further enriching its pipeline and strengthening its market position to address the growing demand for cancer treatments.
See More
Elicio Announces Robust T Cell Responses in Phase 2 Cancer Vaccine Trial
Trial Results: Elicio Therapeutics announced that 99% of patients in its Phase 2 AMPLIFY-7P trial showed strong mKRAS-specific T cell responses after treatment with the investigational cancer vaccine ELI-002 7P, with immune responses increasing 145-fold from baseline.
Future Expectations: The company anticipates final disease-free survival data from the trial by the fourth quarter of 2025, and an independent monitoring committee has recommended that the trial continue without changes, indicating potential efficacy.
See More
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $13
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders succeed in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
See More
Elicio Grants 21,210 Stock Options to New Employee
- Stock Option Grant: On April 15, 2026, Elicio Therapeutics granted 21,210 inducement stock options to a new employee at an exercise price of $11.78 per share, in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at attracting talent and enhancing the company's competitive edge.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, ensuring employee retention and loyalty during the vesting period, which is crucial for maintaining organizational stability.
- Clinical Development Progress: Elicio's ELI-002 7P program targets mKRAS-positive pancreatic and colorectal cancers, aiming to improve patient survival rates through low-cost, rapidly manufactured immunotherapies, with recent data showing a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months, indicating promising clinical outcomes.
- Technological Innovation Advantage: Elicio's Amphiphile technology enhances the education and activation of cancer-specific T cells, offering faster drug availability and lower costs compared to traditional immunotherapy, aligning with market demands for effective and economical treatment options.
See More
Elicio Therapeutics Reports FY GAAP EPS and Cash Position
- Financial Performance: Elicio Therapeutics reported a FY GAAP EPS of -$2.58, indicating challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $18.6 million, an increase from $17.6 million in 2024, reflecting improved cash management practices.
- Operational Support Outlook: The company expects its current cash and projected at-the-market program proceeds to sustain operations into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 event-driven DFS analysis in 1H 2026, demonstrating confidence in future operations.
- Funding Situation: Elicio raised approximately $4.9 million in net proceeds in Q4 2025 and $6.3 million to date in Q1 2026 through its established at-the-market program, enhancing liquidity to support R&D and operations.
See More
Elicio Therapeutics Grants 22,400 Stock Options to Attract New Employees
- Stock Option Incentive: On January 15, 2026, Elicio Therapeutics granted 22,400 inducement stock options to two new employees to attract talent in compliance with Nasdaq Listing Rule 5635(c)(4), which is expected to enhance the company's talent acquisition and team strength.
- Option Pricing: Each stock option is priced at $7.81 per share based on the closing price on the grant date, which will allow employees to gradually acquire company shares over four years, thereby increasing employee loyalty in the long term.
- Clinical Research Progress: Elicio's ELI-002 immunotherapy demonstrated a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months in a randomized trial for mKRAS-positive pancreatic cancer, indicating its potential in cancer treatment and likely driving future market demand.
- Technological Innovation: Elicio's AMP technology aims to enhance the education and activation of cancer-specific T cells, which is expected to provide the company with a strategic advantage in the competitive biotechnology market, particularly in the field of immunotherapy for high-prevalence cancers.
See More
Elicio Grants 157,193 Stock Options to Attract New Employees
- Employee Incentive Program: On December 15, 2025, Elicio granted 157,193 inducement stock options to three new employees, aiming to attract talent while complying with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to talent acquisition.
- Stock Option Details: Each stock option has an exercise price of $8.52 per share, based on the closing price on the grant date, with vesting over four years, reflecting the company's recognition of long-term employee contributions.
- Clinical Development Outlook: Elicio focuses on developing immunotherapies for high-prevalence cancers, particularly ELI-002 for mKRAS-positive pancreatic and colorectal cancers, aiming to meet market demand through low-cost and rapid production, thereby enhancing competitive positioning.
- Future Expansion Plans: Elicio intends to expand ELI-002 to other mKRAS-positive cancers, further enriching its pipeline and strengthening its market position to address the growing demand for cancer treatments.
See More
Elicio Announces Robust T Cell Responses in Phase 2 Cancer Vaccine Trial
Trial Results: Elicio Therapeutics announced that 99% of patients in its Phase 2 AMPLIFY-7P trial showed strong mKRAS-specific T cell responses after treatment with the investigational cancer vaccine ELI-002 7P, with immune responses increasing 145-fold from baseline.
Future Expectations: The company anticipates final disease-free survival data from the trial by the fourth quarter of 2025, and an independent monitoring committee has recommended that the trial continue without changes, indicating potential efficacy.
See More
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $13
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders succeed in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
See More
